Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

Authors:
  • JKJeffrey E. Kropf
    Jeffrey E. Kropf
  • TLTony Lee
    Tony Lee
  • PBPeter Blomgren
    Peter Blomgren
  • JXJianjun Xu
    Jianjun Xu
  • ZZZhongdong Zhao
    Zhongdong Zhao
  • JWJ. Andrew Whitney
    J. Andrew Whitney
  • DMDeborah Maclin
    Deborah Maclin
  • PMPatricia Maciejewski
    Patricia Maciejewski
  • ARAnn Marie Rossi
    Ann Marie Rossi

Abstract
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.

This publication has 49 references indexed in Scilit: